Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for Depression in Parkinson's Disease
KCT0011227Phase 4Not yet recruiting
- Sponsor
- Myungin Pharm
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluoxetine in Parkinson's disease (PD), major depressive disorder (MDD), sponsored by Myungin Pharm. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
fluoxetine
03
Conditions
Parkinson's disease (PD)major depressive disorder (MDD)
Beyond the preview
Go deeper on KCT0011227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0011227.